New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
06:41 EDTIPXLImpax price target raised to $35 from $27 at Piper Jaffray
Piper Jaffray raised its price target for Impax shares to $35 saying it sees more upside potential than downside risk even with the absence of a resolution of the FDA warning letter related to the Hayward manufacturing facility. Piper reiterates an Overweight rating on the stock.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:12 EDTIPXLImpax to release guidance when Tower Holdings, Lineage acquisitions completed
Subscribe for More Information
07:12 EDTIPXLImpax reports Q4 adjusted EPS 16c, consensus 12c
Reports Q4 revenue $131.2M, consensus $125.47M. Reports Q4 Global Pharmaceuticals revenue $117.9M. The increase is due to higher sales of several key generic products as well as the impact of customer credits that were recorded in the prior year period of $19.2 million as a result of customer credits relating to certain pricing activities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use